A Phase 2 interventional study of azacitidine in Myelodysplastic Syndromes, sponsored by Celgene. Completed at 31 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-22.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.
Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 12th largest by enrollment of the 126 interventional ones that give a count, is one of 7 that started in 2005, is one of 63 in phase 2, and was the 5th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70
City of Hope Medical Center · Sites in United States
Ages 18–75
Medical College of Wisconsin · Sites in United States
Ages 18+
Institut de Recherches Internationales Servier · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 86 · Phase 3 12 · Phase 4 3
First in 2000; this study’s year is marked. 7 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 151 is above the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 38 across the 126 interventional studies. Of the 88 that completed or were terminated, 42 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 130 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb: 4 open now, 9 under way, 5 of them phase 3. Of 63 finished, 20 (32%) have results posted.
Among the 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb, this one is the 14th largest by enrollment of the 46 interventional ones that give a count, is one of 5 that started in 2005, is one of 14 in phase 2, and was the 7th registered.
Bristol-Myers Squibb’s Myelodysplastic Syndromes studies by the year they started, since 2001.
9 of the studies testing azacitidine in Myelodysplastic Syndromes that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06465953Phase 3Institut de Recherches Internationales ServierIvosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation | 2027-11-01 |
| NCT05788679Karolinska University HospitalA Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS | 2026-12 |
| NCT00392353National Cancer Institute (NCI)Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | 2026-12-31 |
| NCT06502145Medical College of WisconsinIadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome | 2026-12-31 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, from their registry updates:
Among Bristol-Myers Squibb’s 75 in Myelodysplastic Syndromes:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if azacitidine, combined with Best Supportive Care (BSC), is effective in treating myelodysplastic syndromes (MDS) when given according to a different doses and dosing schedules.
Comparison/Control Interventions: The comparison is azacitidine at different doses and schedules.
Duration of Intervention: Treatment lasted for a maximum of 18 cycles, which is up to 24 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Azacitidine administered subcutaneously at 75mg/m\^2 for 5 days on a 28 day cycle.
Drug: azacitidine
Azacitidine administered subcutaneously at 75mg/m\^2 for 5days with 2 days off, then for an additional 2 days, on a 28 day cycle.
Drug: azacitidine
Azacitidine administered subcutaneously at 50mg/m\^2 for 5 days with 2 days off, then for an additional 5 days, on a 28 day cycle.
Drug: azacitidine
Azacitidine administered subcutaneously at 75mg/m\^2 for 5 days every 4 weeks.
Drug: azacitidine
Azacitidine administered subcutaneously at 75mg/m\^2 for 5 days every 6 weeks.
Drug: azacitidine
Azacitidine is administered subcutaneously Total of 18 cycles on treatment or early discontinuation.
Number of Participants In Best Hematological Response Categories as Determined by the Investigator Using International Working Group 2000 (IWG 2000) Criteria For Myelodysplastic Syndromes (MDS) During the Initial Study Period.
Participant counts by best hematological response; complete remission(CR) is better than a partial remission(PR) which is better than stable disease(SD). Investigator determined responses followed IWG 2000 criteria for MDS CR: repeat bone marrow show \<5% myeloblasts, and peripheral blood evaluations lasting \>=2 months of hemoglobin(\>110 g/L), neutrophils(\>=1.5x10\^9/L), platelets(\>=100x10\^9/L), blasts (0%) and no dysplasia PR is the same as CR for peripheral blood: bone marrow shows blasts decrease by \>=50% or a less advanced FAB classification from pretreatment (see Population Descrip)
Time frame: Day 1 (randomization) to 6 months
Number of Participants With Best Hematological Improvement Derived Using International Working Group 2000 (IWG 2000) Criteria for MDS During the Initial Study Period.
IWG 2000 Criteria: Pretreatment=hemoglobin \<110g/L or RBC transfusion-dependence, platelet count \<100x10\^9/L or platelet transfusion dependence, absolute neutrophil count \<1.5x10\^9/L. Erythroid response: Major-\>20g/L increase in hemoglobin or transfusion independence. Minor- 10-20g/L increase in hemoglobin or \>=50% decrease in transfusion requirements. Platelet response: Major-absolute increase of platelet count by \>=30x10\^9/L or platelet transfusion independence. Minor-\>=50% increase in platelet count with net increase \>10x10\^9/L but \<30x10\^9/L. (continued in Population Description)
Time frame: Day 1 (randomization) to 6 months
Number of Participants With Overall Best Hematologic Response and Hematologic Improvement Based on IWG 2000 Criteria For MDS During the Initial Study Period
Number of participants whose best hematological outcome was either complete remission (CR), partial remission (PR) (as determined by the investigator), or any hematologic improvement (based on the IWG 2000 criteria for MDS). See previous outcomes for detailed definitions.
Time frame: Day 1 (randomization) to 6 months
Number of Participants Who Improved or Maintained The Hematologic Response From the Initial Study Period (Based on IWG 2000 Criteria For MDS) During the Maintenance Period
Hematologic response during the maintenance period are compared to the response in the initial study period. Initial response could have been a complete remission, a partial remission, stable disease or a hematologic improvement. Maintenance period best response is after randomization to a maintenance arm for those randomized, and is after the start of cycle 7 for those remaining on initial period treatment throughout the study.
Time frame: 24 months
Baseline Hemoglobin Values
The median values for hemoglobin based on blood tests performed on study day 1 (prior to study treatment) constitute a baseline measure for hemoglobin. Baseline values are used to compare to values following treatment.
Time frame: Day 1 (randomization)
Change From Baseline in Hemoglobin at End of Initial Study Period (6 Months)
The difference between hemoglobin values at the end of the initial study period minus the hemoglobin values at baseline.
Time frame: 6 months
Change From Baseline in Hemoglobin at the End of the Maintenance Study Period
The difference between hemoglobin values at the end of the maintenance study period minus the hemoglobin values at baseline.
Time frame: 24 months
Baseline Platelet Values
The median values for platelets based on blood tests performed on study day 1 (prior to study treatment) constitute a baseline measure for platelets. Baseline values are used to compare to values following treatment.
Time frame: Day 1 (randomization)
Change From Baseline in Platelets at the End of Initial Study Period (6 Months)
The difference between platelet values at the end of the initial study period minus the platelet values at baseline.
Time frame: 6 months
Change From Baseline in Platelets at the End of the Maintenance Study Period (Month 24)
The difference between platelet values at the end of the maintenance study period minus the platelet values at baseline.
Time frame: 24 months
Baseline Absolute Neutrophil Count (ANC) Values
The median values for ANC based on blood tests performed on study day 1 (prior to study treatment) constitute a baseline measure for ANC. Baseline values are used to compare to values following treatment.
Time frame: Day 1 (randomization)
Change From Baseline in Absolute Neutrophil Count (ANC) at the End of Initial Study Period (6 Months)
The difference between ANC values at the end of the initial study period minus the ANC values at baseline.
Time frame: 6 months
Change From Baseline in Absolute Neutrophil Count (ANC) at the End of the Maintenance Study Period (Month 24)
The difference between ANC values at the end of the maintenance study period minus the ANC values at baseline.
Time frame: 24 months
Red Blood Cell (RBC) Transfusion Status at Baseline and End of Initial Study Period (6 Months)
Shift table comparing the RBC transfusion status of patients at the end of the initial study period to the transfusion status at baseline.
Time frame: 6 months
Platelet Transfusion Status at Baseline and End of Initial Study Period (6 Months)
Shift table comparing the platelet transfusion status of patients at the end of the initial study period to the transfusion status at baseline.
Time frame: 6 months
Red Blood Cell (RBC) Transfusion Status at Baseline and End of Maintenance Study Period (24 Months)
Shift table comparing the RBC transfusion status of patients at the end of the maintenance study period to the transfusion status at baseline.
Time frame: 24 months
Platelet Transfusion Status at Baseline and End of Maintenance Study Period (24 Months)
Shift table comparing the platelet transfusion status of patients at the end of the maintenance study period to the transfusion status at baseline.
Time frame: 24 months
Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Initial Study Period
Baseline uses the average number of infections requiring IV antibiotic treatment from the 28 days prior to and including the day of first dose to an initial treatment arm. Initial study period values total the number of infections requiring IV antibiotic treatment divided by the number of treatment cycles (each cycle is approximately one month).
Time frame: 6 months
Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Maintenance Study Period
Baseline uses the average number of infections requiring IV antibiotic treatment from the 28 days prior to and including the day of first dose to an initial treatment arm. Maintenance study period values total the number of infections requiring IV antibiotic treatment divided by the number of treatment cycles (each cycle is approximately one month).
Time frame: 24 months
| Milestone | Aza-5 | Aza-5-2-2 | Aza-5-2-5 | Maintenance Aza 5 Days q 4 Weeks | Maintenance Aza 5 Days q 6 Weeks |
|---|---|---|---|---|---|
| Started | 50 | 50 | 51 | 0 | 0 |
| Completed | 32 | 22 | 25 | 0 | 0 |
| Not completed | 18 | 28 | 26 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 3 | 5 | 0 | 0 |
| Withdrew: Adverse event | 4 | 7 | 9 | 0 | 0 |
| Withdrew: Transformation to aml (blast > 30%) | 1 | 3 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Physician decision | 2 | 9 | 6 | 0 | 0 |
| Withdrew: Sponsor's decision | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Failed treatments (relapse,disease prog) | 4 | 4 | 2 | 0 | 0 |
| Withdrew: Death | 1 | 1 | 1 | 0 | 0 |
| Milestone | Aza-5 | Aza-5-2-2 | Aza-5-2-5 | Maintenance Aza 5 Days q 4 Weeks | Maintenance Aza 5 Days q 6 Weeks |
|---|---|---|---|---|---|
| Started | 13 | 6 | 8 | 22 | 21 |
| Completed | 6 | 2 | 2 | 12 | 8 |
| Not completed | 7 | 4 | 6 | 10 | 13 |
| Withdrew: Withdrawal by subject | 4 | 0 | 2 | 3 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 | 1 | 3 |
| Withdrew: Transformation to aml (blast > 30%) | 0 | 1 | 0 | 2 | 0 |
| Withdrew: Failed treatment (relapse,disease prog) | 1 | 1 | 1 | 3 | 4 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Physician decision | 1 | 2 | 3 | 0 | 4 |
Participant counts by best hematological response; complete remission(CR) is better than a partial remission(PR) which is better than stable disease(SD). Investigator determined responses followed IWG 2000 criteria for MDS CR: repeat bone marrow show \<5% myeloblasts, and peripheral blood evaluations lasting \>=2 months of hemoglobin(\>110 g/L), neutrophils(\>=1.5x10\^9/L), platelets(\>=100x10\^9/L), blasts (0%) and no dysplasia PR is the same as CR for peripheral blood: bone marrow shows blasts decrease by \>=50% or a less advanced FAB classification from pretreatment (see Population Descrip)
| participants | Aza-5 | Aza-5-2-2 | Aza-5-2-5 |
|---|---|---|---|
| Overall Response (CR+PR) | 4 | 3 | 4 |
| Complete remission (CR) | 2 | 2 | 2 |
| Partial remission (PR) | 2 | 1 | 2 |
| Stable disease | 22 | 19 | 20 |
IWG 2000 Criteria: Pretreatment=hemoglobin \<110g/L or RBC transfusion-dependence, platelet count \<100x10\^9/L or platelet transfusion dependence, absolute neutrophil count \<1.5x10\^9/L. Erythroid response: Major-\>20g/L increase in hemoglobin or transfusion independence. Minor- 10-20g/L increase in hemoglobin or \>=50% decrease in transfusion requirements. Platelet response: Major-absolute increase of platelet count by \>=30x10\^9/L or platelet transfusion independence. Minor-\>=50% increase in platelet count with net increase \>10x10\^9/L but \<30x10\^9/L. (continued in Population Description)
| participants | Aza-5 | Aza-5-2-2 | Aza-5-2-5 |
|---|---|---|---|
| Any Improvement n=50,49,47 | 29 | 20 | 26 |
| Erythroid response - Major n=44,43,41 | 18 | 15 | 18 |
| Erythroid response - Minor n=44,43,41 | 4 | 1 | 2 |
| Platelet response - Major n=24,28,28 | 10 | 11 | 10 |
| Platelet response - Minor n=24,28,28 | 2 | 0 | 0 |
| Neutrophil response - Major n=24,22,16 | 4 | 3 | 3 |
| Neutrophil response - Minor n=24,22,16 | 2 | 0 | 0 |
Number of participants whose best hematological outcome was either complete remission (CR), partial remission (PR) (as determined by the investigator), or any hematologic improvement (based on the IWG 2000 criteria for MDS). See previous outcomes for detailed definitions.
| participants | Aza-5 | Aza-5-2-2 | Aza-5-2-5 |
|---|---|---|---|
| Number of Participants With Overall Best Hematologic Response and Hematologic Improvement Based on IWG 2000 Criteria For MDS During the Initial Study Period | 30 | 20 | 27 |
The median values for hemoglobin based on blood tests performed on study day 1 (prior to study treatment) constitute a baseline measure for hemoglobin. Baseline values are used to compare to values following treatment.
| g/L | Aza-5 | Aza-5-2-2 | Aza-5-2-5 |
|---|---|---|---|
| Baseline Hemoglobin Values | 94.0 (63.0 to 131.0) | 98.0 (70.0 to 135.0) | 95.5 (59.0 to 145.0) |
The difference between hemoglobin values at the end of the initial study period minus the hemoglobin values at baseline.
| g/L | Aza-5 | Aza-5-2-2 | Aza-5-2-5 |
|---|---|---|---|
| Change From Baseline in Hemoglobin at End of Initial Study Period (6 Months) | 2.3 (-25.9 to 41.8) | 2.9 (-33.0 to 31.7) | 5.3 (-20.4 to 30.4) |
Hematologic response during the maintenance period are compared to the response in the initial study period. Initial response could have been a complete remission, a partial remission, stable disease or a hematologic improvement. Maintenance period best response is after randomization to a maintenance arm for those randomized, and is after the start of cycle 7 for those remaining on initial period treatment throughout the study.
| participants | Maintenance Aza 5 Days q 4 Weeks | Maintenance Aza 5 Days q 6 Weeks | Initial Period Treatment Continued Into Maintenance |
|---|---|---|---|
| Improved response from initial study period | 7 | 10 | 12 |
| Maintained response from initial study period | 6 | 5 | 10 |
The difference between hemoglobin values at the end of the maintenance study period minus the hemoglobin values at baseline.
| g/L | Maintenance Aza 5 Days q 4 Weeks | Maintenance Aza 5 Days q 6 Weeks | Initial Period Treatment Continued Into Maintenance |
|---|---|---|---|
| Change From Baseline in Hemoglobin at the End of the Maintenance Study Period | 5.9 (-27.9 to 54.8) | 7.3 (-14.4 to 55.5) | 14.5 (-5.5 to 60.4) |
The median values for platelets based on blood tests performed on study day 1 (prior to study treatment) constitute a baseline measure for platelets. Baseline values are used to compare to values following treatment.
| x10(9)/L | Aza-5 | Aza-5-2-2 | Aza-5-2-5 |
|---|---|---|---|
| Baseline Platelet Values | 110.0 (9.0 to 516.0) | 90.0 (8.0 to 581.0) | 86.0 (8.0 to 699.0) |
The difference between platelet values at the end of the initial study period minus the platelet values at baseline.
| x10^9/L | Aza-5 | Aza-5-2-2 | Aza-5-2-5 |
|---|---|---|---|
| Change From Baseline in Platelets at the End of Initial Study Period (6 Months) | 4.8 (-116.3 to 179.1) | 5.7 (-145.6 to 192.6) | 12.6 (-300.9 to 213.6) |
The difference between platelet values at the end of the maintenance study period minus the platelet values at baseline.
| x10^9/L | Maintenance Aza 5 Days q 4 Weeks | Maintenance Aza 5 Days q 6 Weeks | Initial Period Treatment Continued Into Maintenance |
|---|---|---|---|
| Change From Baseline in Platelets at the End of the Maintenance Study Period (Month 24) | 19.8 (-157.5 to 129.6) | 7.7 (-279.8 to 166.3) | 17.3 (-124.7 to 223.3) |
The median values for ANC based on blood tests performed on study day 1 (prior to study treatment) constitute a baseline measure for ANC. Baseline values are used to compare to values following treatment.
| x10^9/L | Aza-5 | Aza-5-2-2 | Aza-5-2-5 |
|---|---|---|---|
| Baseline Absolute Neutrophil Count (ANC) Values | 1.6 (0.1 to 13.9) | 1.9 (0.1 to 162.3) | 2.3 (0.3 to 139.3) |
The difference between ANC values at the end of the initial study period minus the ANC values at baseline.
| x10^9/L | Aza-5 | Aza-5-2-2 | Aza-5-2-5 |
|---|---|---|---|
| Change From Baseline in Absolute Neutrophil Count (ANC) at the End of Initial Study Period (6 Months) | -0.3 (-4.6 to 1.9) | -0.3 (-35.9 to 1.4) | -0.4 (-9.7 to 8.5) |
The difference between ANC values at the end of the maintenance study period minus the ANC values at baseline.
| x10^9/L | Maintenance Aza 5 Days q 4 Weeks | Maintenance Aza 5 Days q 6 Weeks | Initial Period Treatment Continued Into Maintenance |
|---|---|---|---|
| Change From Baseline in Absolute Neutrophil Count (ANC) at the End of the Maintenance Study Period (Month 24) | -0.1 (-17.6 to 2.0) | -0.2 (-3.1 to 1.9) | -0.4 (-19.0 to 2.3) |
Shift table comparing the RBC transfusion status of patients at the end of the initial study period to the transfusion status at baseline.
| participants | Aza-5 | Aza-5-2-2 | Aza-5-2-5 |
|---|---|---|---|
| Baseline Dependent(n=25,24,22) - 6 mo Independent | 16 | 14 | 13 |
| Baseline Dependent(n=25,24,22) - 6 mo Dependent | 9 | 10 | 9 |
| Baseline Independent(n=25,26,29)- 6 mo Independent | 19 | 16 | 19 |
| Baseline Independent(n=25,26,29) - 6 mo Dependent | 6 | 10 | 10 |
Shift table comparing the platelet transfusion status of patients at the end of the initial study period to the transfusion status at baseline.
| participants | Aza-5 | Aza-5-2-2 | Aza-5-2-5 |
|---|---|---|---|
| Baseline Dependent (n=4,2,1) - 6 mo Independent | 3 | 2 | 0 |
| Baseline Dependent (n=4,2,1) - 6 mo Dependent | 1 | 0 | 1 |
| Baseline Independent(n=46,48,50)- 6 mo Independent | 43 | 42 | 41 |
| Baseline Independent (n=46,48,50) - 6 mo Dependent | 3 | 6 | 9 |
Shift table comparing the RBC transfusion status of patients at the end of the maintenance study period to the transfusion status at baseline.
| participants | Maintenance Aza 5 Days q 4 Weeks | Maintenance Aza 5 Days q 6 Weeks | Initial Period Treatment Continued Into Maintenance |
|---|---|---|---|
| Baseline Dependent (n=6,12,12) - 24 mo Independent | 5 | 12 | 10 |
| Baseline Dependent (n=6,12,12) - 24 mo Dependent | 1 | 0 | 2 |
| Baseline Independent(n=16,9,15)- 24 mo Independent | 15 | 9 | 15 |
| Baseline Independent (n=16,9,15) - 24 mo Dependent | 1 | 0 | 0 |
Shift table comparing the platelet transfusion status of patients at the end of the maintenance study period to the transfusion status at baseline.
| participants | Maintenance Aza 5 Days q 4 Weeks | Maintenance Aza 5 Days q 6 Weeks | Initial Period Treatment Continued Into Maintenance |
|---|---|---|---|
| Baseline Dependent (n=1,1,2) - 24 mo Independent | 1 | 1 | 2 |
| Baseline Dependent (n=1,1,2) - 24 mo Dependent | 0 | 0 | 0 |
| Baseline Independent(n=21,20,25)-24 mo Independent | 21 | 20 | 25 |
| Baseline Independent(n=21,20,25) - 24 mo Dependent | 0 | 0 | 0 |
Baseline uses the average number of infections requiring IV antibiotic treatment from the 28 days prior to and including the day of first dose to an initial treatment arm. Initial study period values total the number of infections requiring IV antibiotic treatment divided by the number of treatment cycles (each cycle is approximately one month).
| infections per cycle | Aza-5 | Aza-5-2-2 | Aza-5-2-5 |
|---|---|---|---|
| Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Initial Study Period | 0.00 (0.00 to 1.00) | 0.00 (0.00 to 1.00) | 0.00 (-0.89 to 7.00) |
Baseline uses the average number of infections requiring IV antibiotic treatment from the 28 days prior to and including the day of first dose to an initial treatment arm. Maintenance study period values total the number of infections requiring IV antibiotic treatment divided by the number of treatment cycles (each cycle is approximately one month).
| infections per cycle | Maintenance Aza 5 Days q 4 Weeks | Maintenance Aza 5 Days q 6 Weeks | Initial Period Treatment Continued Into Maintenance |
|---|---|---|---|
| Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Maintenance Study Period | 0.00 (-1.00 to 0.00) | 0.00 (0.00 to 0.20) | 0.00 (0.00 to 0.67) |
Collected over The 3 groups in the Initial Period cover Day 1-6 months, and up to 24 months for participants that continued that treatment. The 2 Maintenance Period groups cover months 7-24 for subjects who were randomized to 1 of the 2 Maintenance treatment arms.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aza-5 | — | 18/50 (36%) | 49/50 (98%) |
| Aza-5-2-2 | — | 27/50 (54%) | 50/50 (100%) |
| Aza-5-2-5 | — | 22/48 (45.8%) | 46/48 (95.8%) |
| Maintenance Aza 5 Days q 4 Weeks | — | 7/22 (31.8%) | 18/22 (81.8%) |
| Maintenance Aza 5 Days q 6 Weeks | — | 13/21 (61.9%) | 18/21 (85.7%) |
| Event | Aza-5 | Aza-5-2-2 | Aza-5-2-5 | Maintenance Aza 5 Days q 4 Weeks | Maintenance Aza 5 Days q 6 Weeks |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/50 | 5/50 | 1/48 | 0/22 | 3/21 |
| PneumoniaInfections and infestations | 1/50 | 1/50 | 5/48 | 0/22 | 1/21 |
| Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/50 | 4/50 | 0/48 | 2/22 | 1/21 |
| Myelodysplastic syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/50 | 0/50 | 1/48 | 2/22 | 1/21 |
| Urinary tract infectionInfections and infestations | 0/50 | 0/50 | 4/48 | 0/22 | 0/21 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/50 | 2/50 | 3/48 | 0/22 | 0/21 |
| PancytopeniaBlood and lymphatic system disorders | 0/50 | 0/50 | 0/48 | 0/22 | 1/21 |
| Angina pectorisCardiac disorders | 0/50 | 1/50 | 1/48 | 0/22 | 1/21 |
| Cardiac failure congestiveCardiac disorders | 0/50 | 2/50 | 2/48 | 0/22 | 1/21 |
| Myocardial infarctionCardiac disorders | 0/50 | 1/50 | 0/48 | 1/22 | 1/21 |
| Event | Aza-5 | Aza-5-2-2 | Aza-5-2-5 | Maintenance Aza 5 Days q 4 Weeks | Maintenance Aza 5 Days q 6 Weeks |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 31/50 | 31/50 | 23/48 | 2/22 | 6/21 |
| FatigueGeneral disorders | 25/50 | 30/50 | 29/48 | 5/22 | 3/21 |
| ConstipationGastrointestinal disorders | 28/50 | 25/50 | 21/48 | 2/22 | 2/21 |
| Injection site erythemaGeneral disorders | 28/50 | 28/50 | 26/48 | 1/22 | 3/21 |
| NeutropeniaBlood and lymphatic system disorders | 15/50 | 22/50 | 17/48 | 2/22 | 2/21 |
| Injection site painGeneral disorders | 15/50 | 18/50 | 18/48 | 1/22 | 3/21 |
| VomitingGastrointestinal disorders | 18/50 | 12/50 | 13/48 | 1/22 | 2/21 |
| AnaemiaBlood and lymphatic system disorders | 11/50 | 17/50 | 12/48 | 3/22 | 5/21 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 17/50 | 11/50 | 9/48 | 0/22 | 2/21 |
| Oedema peripheralGeneral disorders | 4/50 | 14/50 | 16/48 | 3/22 | 3/21 |
| Age, Continuous(years) | Aza-5 | Aza-5-2-2 | Aza-5-2-5 | Total |
|---|---|---|---|---|
| Median | 76.0 (47 to 93) | 73.0 (37 to 88) | 76.0 (54 to 91) | 75.0 (37 to 93) |
| Sex: Female, Male(Participants) | Aza-5 | Aza-5-2-2 | Aza-5-2-5 | Total |
|---|---|---|---|---|
| Female | 17 | 22 | 14 | 53 |
| Male | 33 | 28 | 37 | 98 |
| Race/Ethnicity, Customized(Participants) | Aza-5 | Aza-5-2-2 | Aza-5-2-5 | Total |
|---|---|---|---|---|
| Caucasian | 47 | 41 | 48 | 136 |
| Black or African American | 0 | 4 | 2 | 6 |
| Asian/Oriental | 1 | 0 | 0 | 1 |
| Hispanic | 2 | 5 | 1 | 8 |
| Other | 0 | 0 | 0 | 0 |
| ECOG Performance Status(Participants) | Aza-5 | Aza-5-2-2 | Aza-5-2-5 | Total |
|---|---|---|---|---|
| 0=Fully active | 12 | 19 | 14 | 45 |
| 1=Restricted | 32 | 23 | 29 | 84 |
| 2=Ambulatory/capable of self care | 3 | 5 | 7 | 15 |
| 3=Capable/limited care | 3 | 3 | 1 | 7 |
| FAB Classification(Participants) | Aza-5 | Aza-5-2-2 | Aza-5-2-5 | Total |
|---|---|---|---|---|
| RA | 22 | 22 | 21 | 65 |
| RARS | 7 | 7 | 7 | 21 |
| RAEB | 14 | 14 | 17 | 45 |
| RAEB-T | 2 | 1 | 1 | 4 |
| CMMoL with <5% blasts | 3 | 3 | 1 | 7 |
| CMMoL with >=5% blasts | 2 | 1 | 1 | 4 |
| CMMoL with missing blasts | 0 | 2 | 3 | 5 |
| AML | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 |
| Transfusion Dependence - Platelets(Participants) | Aza-5 | Aza-5-2-2 | Aza-5-2-5 | Total |
|---|---|---|---|---|
| Platelet transfusion dependent | 4 | 2 | 1 | 7 |
| Not platelet transfusion dependent | 46 | 48 | 50 | 144 |
| Transfusion Dependence Status - RBCs(Participants) | Aza-5 | Aza-5-2-2 | Aza-5-2-5 | Total |
|---|---|---|---|---|
| RBC transfusion dependent | 25 | 24 | 22 | 71 |
| Not RBC transfusion dependent | 25 | 26 | 29 | 80 |
Ran from Jan 2005 to primary completion in Aug 2008, 43 months.
Results were first posted in May 2010, 1 year 9 months after primary completion.
Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 43 months is close to that.
Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azacitidine